Scribe Therapeutics, Inc.

SCTX · XNAS

CIK 1853921fmd_1Y04QGHWC0KYBEWS3H5WZF8KQEManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2025 to Sep 30, 2026, 6 periods

AI-written

A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.